在讨论CYP2D6*10突变位点时，常见的表示方式如C188T和C100T均不完整。准确的表述应当以rs号作为唯一标识。然而，在实际操作中，公司可能不会在材料中明确列出rs号。对于CYP2D6*10的具体位点，正确的表示方式为c.100C＞T。通过NCBI-Clinvar数据库查询，可以得知该突变为NM_000106.6(CYP2D6):c.100C...
①一般来说C188T和C100T这种写法都不完整。rs号是SNP的唯一代码。但是一般公司在编材料的时候都不把rs...
CYP2D6*10 (rs1065852)位点基因分型Taqman探针结果如图1。 图1 CYP2D6*10(c.100 C>T)位点基因分型Taqman探针结果 Fig.1 Result of CYP2D6*10 (c.100 C>T) genotyping by Taqman PCR. A: Amplification plot of CYP2D6*10 (c.100 C>T) CC genotype; B: Amplification plot of CYP2D6*10 (c.100...
本发明公开了一种焦磷酸测序法检测他莫昔芬个体化用药基因多态性试剂盒及方法.具体是指CYP2D6*10(rs1065852)和(SULT1A1*2)(rs9282861)单核苷酸多态性.试剂盒包含如SEQIDNO.3-8所示的引物.本发明的试剂盒,可以实现准确,快捷,高通量CYP2D6*10(rs1065852)和SU... 周宏灏 被引量: 0发表: 0年 Clinical im...
However, the effects of the CYP2D6*10 (rs1065852) mutation on the pharmacokinetics of iloperidone in clinical practice remain unknown. Compared to healthy volunteers, it is difficult to perform classic pharmacokinetic studies with rich blood samples from patients due to ethical considerations and ...
The CYP2D6*10 gene variant (rs1065852C>T) is reported to be commonly found in Asian and South Asian populations. The present study was undertaken to design a novel pharmacogenetic assay (Single step-Tetra Arms Polymerase Chain Reaction) for the identification of the CYP2D6*10 variant and ...
本发明的试剂盒利用高度特异的引物对CYP2D6(rs1065852)进行精准的靶向扩增,结合Taqman探针高特异性、快速简便的优点实现CYP2D6(rs1065852)的基因分型。权利要求书1页说明书4页序列表1页附图2页CN112695097B2022.08.19CN112695097B1.一种用于区分假基因CYP2D7P和CYP2D8P从而扩增和分型CYP2D6*10遗传多态性的引物...
一种区分CYP2D7P和CYP2D8P的CYP2D6*10遗传多态性检测试剂盒.pdf,本发明公开了一种区分CYP2D7P和CYP2D8P的CYP2D6*10遗传多态性检测试剂盒,属于分子医学技术领域。本发明的试剂盒利用高度特异的引物对CYP2D6(rs1065852)进行精准的靶向扩增,结合Taqman探针高特异性、快速简
7.针对上述现有技术的不足,本发明提供了一种用以区分假基因cyp2d7p和cyp2d8p从而精准扩增和分型cyp2d6*10遗传多态性的检测试剂盒,利用高度特异的引物对cyp2d6(rs1065852)进行精准的靶向扩增,结合taqman探针高特异性、快速简便的优点实现cyp2d6(rs1065852)的基因分型。
We determined the relative catalytic activities of CYP2D6*1 and CYP2D6*10 for metabolizing AMMC and bufu- ralol and gained an understanding of the effects of the inhibi- tors on the variants of CYP2D6. In the initial screening study, six phytochemicals competitively inhibited CYP2D6*1- and ...